Effects of vascular risk factors, statins, and antihypertensive drugs on PiB deposition in cognitively normal subjects

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Volumn 2, Issue , 2016, Pages 95-104

  Glodzik, Lidia ^a   Rusinek, Henry ^a   Kamer, Angela ^b   Pirraglia, Elizabeth ^a   Tsui, Wai ^a   Mosconi, Lisa ^a   Li, Yi ^a   McHugh, Pauline ^a   Murray, John ^a   Williams, Schantel ^c   Osorio, Ricardo S ^a   Randall, Catherine ^a   Butler, Tracy ^a   Deshpande, Anup ^a   Vallabhajolusa, Shankar ^d   de Leon, Mony ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c RENAL RESEARCH INSTITUTE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Amyloid; Antihypertensive medications; Brain; Diuretics; Healthy elderly; PET PiB; Statins angiotensin receptor blockers; Vascular risk factors

Indexed keywords

AMYLOID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN E; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PITTSBURGH COMPOUND B;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; COGNITION; CROSS-SECTIONAL STUDY; FEMALE; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMAGE PROCESSING; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OBESITY; PET SCANNER; POSITRON EMISSION TOMOGRAPHY;

EID: 84964827431     PISSN: None     EISSN: 23528729     Source Type: Journal    
DOI: 10.1016/j.dadm.2016.02.007     Document Type: Article

References (53)

1. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004, 5:347-360.
2. De La Torre J.C. Carotid artery ultrasound and echocardiography testing to lower the prevalence of Alzheimer's disease. J Stroke Cerebrovasc Dis 2009, 18:319-328.
3. Farkas E., Luiten P.G.M. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 2001, 64:575-611.
4. Zlokovic B.V. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 2011, 12:723-738.
5. Kivipelto M., Ngandu T., Fratiglioni L., Viitanen M., Kareholt I., Winblad B., et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 2005, 62:1556-1560.
6. Yarchoan M., Xie S.X., Kling M.A., Toledo J.B., Wolk D.A., Lee E.B., et al. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain 2012, 135:3749-3756.
7. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
8. Lee P.H., Hwang E.M., Hong H.S., Boo J.H., Mook-Jung I., Huh K. Effect of ischemic neuronal insults on amyloid precursor protein processing. Neurochem Res 2006, 31:821-827.
9. Sun X., He G., Qing H., Zhou W., Dobie F., Cai F., et al. Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. PNAS 2006, 103:18727-18732.
10. Langbaum J.B., Chen K., Launer L.J., Fleisher A.S., Lee W., Liu X., et al. Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons. Neurobiol Aging 2012, 33:827.e11-827.e19.
11. Rodrigue K.M., Rieck J.R., Kennedy K.M., Devous M.D., Diaz-Arrastia R., Park D.C. Risk factors for ß-amyloid deposition in healthy aging: vascular and genetic effects. JAMA Neurol 2013, 70:600-606.
12. Toledo J.B., Toledo E., Weiner M.W., Jack C.R., Jagust W., Lee V.M.Y., et al. Cardiovascular risk factors, cortisol, and amyloid-b deposition in Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement 2012, 8:483-489. for the Alzheimer's Disease Neuroimaging Initiative.
13. Hughes T.M., Lopez O.L., Evans R.W., Kamboh M.I., Williamson J.D., Klunk W.E., et al. Markers of cholesterol transport are associated with amyloid deposition in the brain. Neurobiol Aging 2014, 35:802-807.
14. Reed B., Villeneuve S., Mack W., DeCarli C., Chui H.C., Jagust W. Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol 2014, 71:195-200.
15. Vidoni E.D., Townley R.A., Honea R.A., Burns J.M. Alzheimer disease biomarkers are associated with body mass index. Neurology 2011, 77:1913-1920. for the Alzheimer's Diasease Neuroimaging Initiative.
16. Munro C.A. Sex differences in Alzheimer's disease risk: are we looking at the wrong hormones?. Int Psychogeriatr 2014, 26:1579-1584.
17. Kim S., Kim M.J., Kim S., Kang H.S., Lim S.W., Myung W., et al. Gender differences in risk factors for transition from mild cognitive impairment to Alzheimer's disease: A CREDOS study. Compr Psychiatry 2015, 62:114-122.
18. Ancelin M.L., Ripoche E., Dupuy A.M., Barberger-Gateau P., Auriacombe S., Rouaud O., et al. Sex Differences in the associations between lipid levels and incident dementia. J Alzheimers Dis 2013, 34:519-528.
19. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
20. Reisberg B., Sclan S.G., Franssen E.H., de Leon M.J., Kluger A., Torossian C.L., et al. Clinical stages of normal aging and Alzheimer's disease: The GDS staging system. Neurosci Res Commun 1993, 13(Suppl 1):551-554.
21. Weintraub S., Salmon D., Mercaldo N., Ferris S., Graff-Radford N.R., Chui H., et al. The Alzheimer's Disease Centers' Uniform Data Set (UDS): The Neuropsychologic Test Battery. Alzheimer Dis Assoc Disord 2009, 23:91-101.
22. Gilbert J.G. Guild Memory Test Manual 1970, UNICO National Mental Health Research Center, Newark, NJ.
23. De Santi S., Pirraglia E., Barr W.B., Babb J., Williams S., Rogers K., et al. Robust and conventional neuropsychological norms: Diagnosis and prediction of age-related cognitive decline. Neuropsychology 2008, 22:469-484.
24. Pirraglia E., Lobach I., De Santi S., Karantzoulis S., Glodzik L., de Leon M.J. Comparison of methods for deriving normative scores for evaluating cognitive impairment. Alzheimers Dement 2012, 8:P541-P542.
25. Chobonian A., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003, 289:2560-2572.
26. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high cholesterol in adults (Adult Treatment panel III). Final Report. Circulation 2002, 106:3143. NIH Publication No.02-5125, US Department of Health and HUman Services NIoHNHLaBI.
27. Main B.F., Jones P.J., MacGillivray R.T., Banfield D.K. Apolipoprotein E genotyping using the polymerase chain reaction and allele-specific oligonucleotide primers. J Lipid Res 1991, 32:183-187.
28. Tsui W.H., Rusinek H., Van Gelder P., Lebedev S. Analyzing multi-modality tomographic images and associated regions of interest with MIDAS. Proceedings of SPIE Medical Imaging: Image Processing 2001, 4322:1725-1734.
29. Ashburner J., Friston K.J. Voxel-based morphometry-the methods. Neuroimage 2000, 11:805-821.
30. Li Y., Rinne J.O., Mosconi L., Pirraglia E., Rusinek H., De Santi S., et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2008, 35:2169-2181.
31. Li N.C., Lee A., Whitmer R.A., Kivipelto M., Lawler E., Kazis L.E., et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010, 340:b5465.
32. Hajjar I., Brown L., Mack W.J., Chui H. Impact of angiotensin receptor blockers on Alzheimer Disease neuropathology in a large brain autopsy series. Arch Neurol 2012, 69:1632-1638.
33. Kurata T., Lukic V., Kozuki M., Wada D., Miyazaki K., Morimoto N., et al. Telmisartan reduces progressive accumulation of cellular amyloid Beta and phosphorylated Tau with inflammatory responses in aged spontaneously hypertensive stroke resistant rat. J Stroke Cerebrovasc Dis 2014, 23:2580-2590.
34. Ongali B., Nicolakakis N., Tong X.K., Aboulkassim T., Papadopoulos P., Rosa-Neto P., et al. Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer's disease model. Neurobiol Dis 2014, 68:126-136.
35. Anderson C., Teo K., Gao P., Arima H., Dans A., Unger T., et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol 2011, 10:43-53.
36. Benicky J., Sanchez-Lemus E., Honda M., Pang T., Orecna M., Wang J., et al. Angiotensin II AT1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology 2011, 36:857-870.
37. Saavedra J.M., Benicky J., Zhou J. Angiotensin II: multitasking in the brain. J Hypertens Suppl 2015, 24:S131-S137.
38. Khachaturian A.S., Zandi P.P., Lyketsos C.G., Hayden K.M., Skoog I., Norton M.C., et al. Antihypertensive medication use and incident Alzheimer Disease: The Cache County Study. Arch Neurol 2006, 63:686-692. for the Cache County Study Group.
39. Yasar S., Lin F.M., Fried L.P., Kawas C.H., Sink K.M., DeKosky S.T., et al. Diuretic use is associated with better learning and memory in older adults in the Ginkgo Evaluation of Memory study. Alzheimers Dement 2012, 8:188-195.
40. Yasar S., Xia J., Yao W., Furberg C.D., Xue Q.L., Mercado C.I., et al. Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology 2013, 81:896-903. For the Ginkgo Evaluation of Memory (GEM) Study Investigators.
41. Zhao W., Wang J., Ho L., Ono K., Teplow D.B., Pasinetti G.M. Identification of Antihypertensive drugs which inhibit amyloid-β protein oligomerization. J Alzheimers Dis 2009, 16:49-57.
42. Shinohara M., Sato N., Kurinami H., Shimamura M., Hamasaki T., Chatterjee A., et al. Possible modification of Alzheimer Disease by statins in midlife: Interactions with genetic and non-genetic risk factors. Front Aging Neurosci 2014, 6:71.
43. Arvanitakis Z., Schneider J.A., Wilson R.S., Bienias J.L., Kelly J.F., Evans D.A., et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 2008, 70:1795-1802.
44. Vance J.E., Karten B., Hayashi H. Lipid dynamics in neuron. Biochem Soc Trans 2006, 34:399-403.
45. Goldstein M.R., Mascitelli L. Regarding long-term statin therapy: Are we trading stronger hearts for weaker brains?. Med Hypotheses 2014, 83:346-351.
46. Preiss D., Sattar N. Statins and new-onset diabetes-the important questions. Nat Rev Cardiol 2012, 9:190.
47. Sano M., Bell K.L., Galasko D., Galvin J.E., Thomas R.G., van Dyck C.H., et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 2011, 77:556-563.
48. Feldman H.H., Doody R.S., Kivipelto M., Sparks D.L., Waters D.D., Jones R.W., et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010, 74:956-964. On behalf of the LEADe Investigators.
49. Padala K.P., Padala P.R., McNeilly D.P., Geske J.A., Sullivan D.H., Potter J.F. The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer's Dementia: A prospective withdrawal and rechallenge pilot study. Am J Geriatr Pharmacother 2012, 10:296-302.
50. Strom B.L., Schinnar R., Karlawish J., Hennessy S., Teal V., Bilker W.B. Statin therapy and risk of acute memory impairment. JAMA Intern Med 2015, 175:1399-1405.
51. Cox A.J., West N.P., Cripps A.W. Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol 2015, 3:207-215.
52. Pradhan A.D. Sex Differences in the metabolic syndrome: Implications for cardiovascular health in women. Clin Chem 2014, 60:44-52.
53. Abraham H.M., Wolfson L., Moscufo N., Guttmann C.R.G., Kaplan R.F., White W.B. Cardiovascular risk factors and small vessel disease of the brain: Blood pressure, white matter lesions, and functional decline in older persons. J Cereb Blood Flow Metab 2016, 36:132-142.